Jason Johnson Selected Research

Atherosclerosis

11/2021	Disparate effects of MMP and TIMP modulation on coronary atherosclerosis and associated myocardial fibrosis.
1/2013	Hematopoietic sphingosine 1-phosphate lyase deficiency decreases atherosclerotic lesion development in LDL-receptor deficient mice.
11/2002	An external, oversized, porous polyester stent reduces vein graft neointima formation, cholesterol concentration, and vascular cell adhesion molecule 1 expression in cholesterol-fed pigs.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jason Johnson Research Topics

Disease

3	Atherosclerosis 11/2021 - 11/2002
2	Neoplasms (Cancer) 08/2023 - 12/2016
2	Brain Neoplasms (Brain Tumor) 08/2023 - 05/2023
2	Neoplasm Metastasis (Metastasis) 08/2023 - 01/2023
2	Infarction (Infarctions) 11/2021 - 11/2005
2	Schizophrenia (Dementia Praecox) 12/2013 - 06/2010
1	Breast Neoplasms (Breast Cancer) 08/2023
1	Ataxia Telangiectasia (Louis Bar Syndrome) 08/2023
1	Necrosis 11/2022
1	Fibrosis (Cirrhosis) 11/2021
1	Heart Failure 11/2021
1	Atherosclerotic Plaque (Atheroma) 11/2021
1	Sudden Death 11/2021
1	Coronary Artery Disease (Coronary Atherosclerosis) 11/2021
1	Myocardial Infarction 11/2021
1	Plasmacytoma 10/2021
1	Hemorrhage 01/2021
1	Metabolic Diseases (Metabolic Disease) 08/2018
1	Obesity 08/2018
1	Vascular Remodeling 01/2016
1	Hyperlipidemias (Hyperlipidemia) 01/2016
1	Hyperplasia 01/2016
1	Pain (Aches) 12/2013
1	Sleepiness 12/2013
1	Weight Gain 12/2013
1	Sleep Initiation and Maintenance Disorders (Insomnia) 12/2013
1	Headache (Headaches) 12/2013
1	Tuberous Sclerosis (Bourneville's Disease) 08/2013
1	Lymphopenia (Lymphocytopenia) 01/2013
1	Delirium 06/2010
1	Internal Hernia 11/2005
1	Rupture 03/2005
1	Body Weight (Weight, Body) 03/2005
1	Hypercholesterolemia 11/2002
1	Neointima 11/2002

Drug/Important Bio-Agent (IBA)

2	Apolipoproteins E (ApoE)IBA 11/2021 - 01/2016
2	ApolipoproteinsIBA 11/2021 - 03/2005
2	Olanzapine (Zyprexa)FDA Link 12/2013 - 06/2010
2	CholesterolIBA 03/2005 - 11/2002
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 08/2023
1	human ERBB2 proteinIBA 08/2023
1	talazoparibIBA 08/2023
1	Poly Adenosine Diphosphate RiboseIBA 08/2023
1	Biomarkers (Surrogate Marker)IBA 08/2023
1	Hormones (Hormone)IBA 08/2023
1	Protons (Proton)IBA 11/2022
1	Tissue Inhibitor of Metalloproteinase-2IBA 11/2021
1	Matrix Metalloproteinase InhibitorsIBA 11/2021
1	Matrix Metalloproteinases (MMPs)IBA 11/2021
1	CalciumIBA 01/2021
1	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2016
1	Proteins (Proteins, Gene)FDA Link 01/2016
1	Cathepsin KIBA 01/2016
1	Glucose (Dextrose)FDA LinkGeneric 12/2013
1	trans-sodium crocetinate (crocetin)IBA 08/2013
1	LyasesIBA 01/2013
1	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 01/2013
1	LDL Receptors (LDL Receptor)IBA 01/2013
1	CytokinesIBA 01/2013
1	Pravastatin (Pravachol)FDA LinkGeneric 03/2005
1	Cell Adhesion MoleculesIBA 11/2002
1	PolyestersIBA 11/2002
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 11/2002

Therapy/Procedure

2	Radiotherapy 01/2023 - 11/2022
2	Gastric Bypass (Roux-en-Y Gastric Bypass) 08/2018 - 11/2005
1	Re-Irradiation 05/2023
1	Nephrectomy 10/2021
1	Bariatric Surgery 08/2018
1	Ligation 01/2016
1	Injections 06/2010
1	Stents 11/2002